|
Nebius Group
Nebius celebrates healthcare and life sciences innovators at expanded AI Discovery Awards
Amsterdam, July 2, 2026 — Nebius, the AI cloud company, today announced the winners of the AI Discovery Awards, its annual showcase of leading startups that are using AI to deliver advances in healthcare and life sciences. The 2026 program added Medical Devices and Medical Imaging to the existing BioPharma, Genomics, and Digital Health tracks, reflecting the growing role of AI in connected medical equipment and diagnostic imaging, where inference-intensive workloads are beginning to reshape clinical practice. Nebius congratulates the following winners in each category:
Dr. Ilya Burkov, Global Head of Healthcare & Life Sciences at Nebius, said: “Our winners – and indeed all of the 647 submissions we reviewed – reflect how rapidly AI is changing the pace of healthcare research. Across all categories, startups are compressing timelines that once took years into months or even weeks, and bringing capabilities to clinical and laboratory settings that simply did not exist before. The AI Discovery Awards exist to accelerate that momentum, and to connect the most promising teams with the compute resources, investor networks, and mentorship they need to move from promising research to bringing products to market.” Alongside the awards program, Nebius previewed the Nebius Scientific AI and Healthcare Platform, AI infrastructure built to meet the specialist needs of healthcare and life sciences organizations. Developed in collaboration with teams from across biotech, pharma, digital health, academia, and research institutions, the Nebius Scientific AI and Healthcare Platform is built around two primary use cases: private model hosting gives biotech and pharmaceutical organizations the ability to securely host proprietary models without dedicated GPU overhead; while “Bring your Own Job” supports the custom, reproducible scientific workflows that researchers prefer over standard inference endpoints. Now in their second year, the AI Discovery Awards are a core part of Nebius’s broader commitment to supporting startups and enterprises developing AI applications in healthcare and life sciences. Previous winners have included Transcripta Bio, Slingshot AI, Converge Bio and Prima Mente. This year’s awards ceremony was held at Town Hall by Bottaccio, London. The 2026 AI Discovery Awards were open to companies from pre-seed through to Series D that put AI and machine learning at the core of their product. Category winners were selected from 647 applications received from around the world by an independent panel of 28 judges representing leading pharmaceutical companies, academic institutions, and venture capital firms. Submissions were evaluated based on the use of AI within the product, use of compute, technical innovation, functionality and advantages, performance and efficiency, global impact, and market potential and business sustainability. Category winners each received $100,000 in compute and inference credits, with second and third place receiving $50,000 and $30,000, respectively, in compute credits.
In addition, Regional Trailblazer awards recognizing exceptional companies advancing AI in healthcare and life sciences around the globe were awarded for the first time. Winners each received $30,000 in compute credits: Check Me (Africa), Hummingbird Bioscience (APAC), Owkin (EMEA), Arkangel AI (Latin America), and Xaira Therapeutics (North America). A full list of shortlisted companies, as well as qualification criteria and a jury list, can be found on Nebius’s website at: https://nebius.com/ai-discovery-award. About NebiusNebius, the AI cloud company, is building the full-stack platform for developers and companies to take charge of their AI future — from data and model training to production deployment. Founded on deep in-house technological expertise and operating at scale with a rapidly expanding global footprint, Nebius serves startups and enterprises building AI products, agents, and services worldwide. Nebius is listed on Nasdaq (Nasdaq: NBIS) and headquartered in Amsterdam. For more information please visit www.nebius.com. Media kit nebius.com/media-kit.
ContactsMedia relations: media@nebius.com Investor relations: askIR@nebius.com
Disclaimer
Forward-looking statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our future financial and business performance, strategy, expected growth, planned investments and capital expenditures, capacity expansion plans, anticipated future financing transactions and expected financial results, are forward-looking statements. The words "anticipate," "believe," "continue," "estimate," "expect," "guide," "intend," "likely," "may," "will" and similar expressions and their negatives are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. Actual results may differ materially from the results predicted or implied by such statements, and our reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted or implied by such statements include, among others: market, macroeconomic and geopolitical conditions; our ability to build, operate and manage our businesses to the desired scale; competitive pressures; technological developments; our ability to secure and retain clients; our ability to secure additional capital to enable the growth of the business; unpredictable sales cycles; and potential pricing pressures; as well as those risks and uncertainties related to our continuing businesses included under the captions "Risk Factors" and "Operating and Financial Review and Prospects" in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 30, 2026, which is available on our investor relations website at https://nebius.com/investor-hub and on the SEC website at www.sec.gov. All information in this press release is as of the date hereof (unless stated otherwise). Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
2358364 02-Jul-2026
